Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Mol. Biosci.

Sec. Bioenergetics

Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1648209

Effects of Chemical Modifications on Hemoglobin's Toxicity Towards Human Cardiac Myocytes

Provisionally accepted
  • United States Food and Drug Administration, Silver Spring, United States

The final, formatted version of the article will be published soon.

Background: Hemoglobin-based oxygen carriers (HBOCs) also known as blood substitutes were developed by chemical or genetic alterations of cell-free human or bovine Hbs to prolong the circulation time of Hb and to improve its ability to unload oxygen. However, toxicity and safety issues led to the termination of several clinical trials. The most persistent observation was the development of cardiac lesions after transfusion of some HBOCs in animal models. Oxidation of HBOCs in circulation, subsequent heme release and cellular uptake are thought to play an important role in the overall toxicity of HBOCs.We examined the effects of different redox states, ferrous (Fe +2 ), ferric (Fe +3 ) and ferryl (Fe +4 ) of four different HBOCs on cardiomyocyte integrity and mitochondrial respiration. The HBOC formulations used in this study were two-human derived and two bovine-derived molecules. We analyzed cellular and subcellular impacts of these forms including mitochondrial electron transport chain (ETC) complexes individually by measuring the enzymatic activities of Complex I, Complex II-III, and Complex IV.The ferrous, and ferric forms of these HBOCs generally induced minimum lactate dehydrogenase (LDH) release from human cardiac myocytes (AC16). Meanwhile higher oxidation state, ferryl forms of all HBOCs generated substantial cell injury as measured by LDH levels. We examined the effects of these redox forms of HBOCs and their ability to impair bioenergetic function of cultured AC16 cells. The ferrous forms of HBOCs did not cause measurable impairment of mitochondrial ETC functions, whereas ferric non-functional versions of all the HBOCs caused a significant loss of Complex IV activity but not Complex I or II-III in those cardiac cell lines. On the other hand, complex I, II-III and IV activities were completely blunted by the ferryl forms of HBOCs.This study for the first time investigated the impact of different chemical modifications on the redox activities of HBOCs towards mitochondrial complexes in cardiac myocytes. Higher oxidation ferryl states once formed trigger cellular and subcellular changes in cardiac myocytes. Our findings on the impact of HBOC redox states on mitochondrial function may therefore inform future design of alternative molecular entities to ensure safety and minimize toxicity.

Keywords: Hemoglobin-based oxygen carriers (HBOCs), redox reactions, Mitochondrial fractions, Cardiac AC16, Cytotoxicity

Received: 16 Jun 2025; Accepted: 11 Aug 2025.

Copyright: © 2025 Jana, Garbus-Grant, Kassa and Alayash. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Sirsendu Jana, United States Food and Drug Administration, Silver Spring, United States
Abdu Alayash, United States Food and Drug Administration, Silver Spring, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.